Erlotinib is a first-line molecular targeted therapy for TNBC and many other HER1-overexpressing cancers that functions by specifically inhibiting the tyrosine kinase activity of HER1 through competitively occupying the adenosine triphosphate (ATP) binding site in the intracellular domains of HER1 [26]. Here, EGFR is linked to cancer.